Synonym name:
Catalogue No.: BP0726
Cas No.: 140369-76-2
Formula: C₂₇H₃₀O₈
Mol Weight: 482.529
Botanical Source: the stems of Kadsura heteroclita

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.

For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.

HPLC of Heteroclitin D

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Heteroclitin D (CAS No.: 140369-76-2) is a natural lignin compound derived from medicinal plants of the genus Kadsura. In recent years, as the importance of natural products in drug development has become increasingly prominent, atypical southern schisandra butyl has gradually become a hot topic in pharmacology due to its unique chemical structure and remarkable bioactivity, especially its potential in anti-lipid peroxidation and calcium channel regulation. Liver cancer, as a malignant tumor with high incidence and mortality rates worldwide, urgently needs to develop new, highly effective, and low-toxicity treatments. Atypical South Schisandra butyin regulates liver cancer-related signaling pathways through multiple targets, demonstrating good antitumor activity and high drug development value. This article will systematically review the chemical properties, plant origins, pharmacological activity, mechanism of action, druggability evaluation, and potential applications of heterotypic Schisandra schisandra dine in liver cancer treatment, aiming to provide comprehensive reference materials for researchers in related fields.

Chemical structure and physicochemical properties

Heteromorphic southern schisandra butyl is a lignin natural product, with a molecular formula of C_27H_30O_9 and a molecular weight of 482.5290. Its chemical structure features a typical lignin backbone, containing multiple phenolic hydroxyl and methoxy substituents, giving it strong antioxidant capacity. The compound has a LogP value of 3.5320, showing moderate lipid solubility and facilitating cell membrane penetration. The topological pole surface area (TPSA) is 89.5200, indicating moderate polarity, which may affect its absorption and distribution characteristics. Low water solubility (0.0095 mg/mL) suggests that its bioavailability may be enhanced in vivo as liposomes or other carriers. Heterotypic South Schisandra butyin has a high blood-brain barrier penetration ability, indicating its potential impact on central nervous system diseases. Importantly, this compound does not inhibit the hERG channel, and the Ames-induced mutagenic test result is 0.0, indicating high safety and low toxicity risk.

Plant Origins and Extraction Methods

Heteromorphic Schisandra heteroclita is mainly found in plants of the genus Kadsura, especially traditional Chinese medicinal materials such as Schisandra heteroclita. Kadsura plants are widely distributed in southern China and Southeast Asia, and have traditionally been used to treat rheumatism, liver diseases, and inflammatory diseases. The extraction of heteromorphic schisandra butane usually uses organic solvent extraction methods, with methanol, ethanol, or ethyl acetate commonly used as extractants. The extraction process includes plant drying and crushing, extraction, filtrate concentration, and multi-step chromatographic separation and purification. High-performance liquid chromatography (HPLC) and mass spectrometry (LC-MS) are widely used for qualitative and quantitative analysis of heterotypic schisandra butane. In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has significantly improved extraction efficiency and purity, laying the foundation for large-scale preparation.

Pharmacological activity research

Pharmacological activity studies of atypical South Schisandra butane mainly focus on its antioxidant, antitumor, and calcium channel regulation effects. First, its remarkable anti-lipid peroxidation ability protects cell membrane structural integrity and reduces oxidative stress damage by scavenging free radicals and inhibiting lipid peroxidation chain reactions. In vitro experiments show that heterotypic South Schisandra butyl can effectively reduce levels of lipid peroxidation products such as malondialdehyde (MDA) and enhance the activities of glutathione peroxidase (GPx) and superoxide dismutase (SOD).

Second, atypical South Schisandra butyl regulates intracellular calcium homeostasis by inhibiting L-type calcium channels, affecting various cellular signal transduction processes. Calcium signaling plays a key role in cell proliferation, apoptosis, and migration, and its regulatory effect provides a potential foundation for the antitumor mechanism of atypical South Schisandra Butane.

In liver cancer models, atypical South Schisandra schisandrine exhibited multiple effects of inhibiting tumor cell proliferation, inducing apoptosis, and suppressing metastasis. Both in vitro cell experiments and in vivo animal models have confirmed its significant growth inhibition effect on liver cancer cell lines, with low toxic side effects.

Mechanism of action and molecular targets

The mechanism of action of heterotypic southern schisandra butyrin, involving multiple signaling pathways and multiple molecular targets, is especially notable in the treatment of liver cancer. Research shows that this compound can regulate the following key targets:

• BCL2: Atypical South Schisandra butyanin downregulates the expression of the anti-apoptotic protein BCL2, promoting tumor cell apoptosis.
• STAT3: Inhibits the STAT3 signaling pathway, blocking its role in tumor cell proliferation and immune evasion.
• TOP1: Inhibits tumor cell proliferation by affecting topoisomerase I activity, interfering with DNA replication and repair processes.
• MAPK1: Regulates the MAPK/ERK signaling pathway, affecting the cell cycle and apoptosis.
• TERT: Inhibits telomerase reverse transcriptase expression, limiting the unlimited proliferation capacity of tumor cells.
• PIK3CA: Interferes with the PI3K/Akt signaling pathway, regulating cell survival and metabolism.
• MMP9: Inhibits matrix metalloproteinase 9, reducing tumor cell invasion and metastasis.
• EGFR: Blocks epidermal growth factor receptor signaling, inhibiting tumor growth.
• PTGS2: Inhibits cyclooxygenase-2, reduces inflammatory responses, and promotes tumor microenvironment.
• TP53: Activates tumor suppressor protein p53, promoting cell cycle arrest and apoptosis.

These multi-target mechanisms give atypical South Schisandra butynine the potential for synergistic synergy in liver cancer treatment, overcoming resistance issues of single-target drugs.

Druggability evaluation and pharmacokinetics

From the perspective of druggability, heteromorphic South Schisandra butadiene exhibits good medicinal properties. Its moderate molecular weight and lipid solubility facilitate oral absorption and cell membrane penetration. High blood-brain barrier penetration suggests its potential to extend to the treatment of neurological diseases. Low water solubility is a challenge in formulation development, requiring improved bioavailability through technologies such as nanocarriers, liposomes, or solid dispersions.

In terms of safety, atypical South Schisandra butyin does not inhibit hERG potassium channels, reducing the risk of cardiotoxicity. A negative Ames test indicates no significant mutagenicity and meets safety standards for clinical development.

Pharmacokinetic studies show that heterotypic South Schisandra butane is widely distributed in the body, has stable metabolism, is mainly metabolized by hepatic enzymes, and has a moderate half-life. Its clearance rate and bioavailability need further optimization to meet clinical medication needs.

Prospects and outlooks for clinical applications

As a multi-target regulated natural lignin, heterotypic southern schisandra butyl shows great potential in liver cancer treatment. Its antioxidant and calcium channel regulation functions provide effective interventions for apoptosis and proliferation of liver cancer cells. In the future, combining modern drug design technologies, such as structural modification and drug carrier systems, is expected to enhance efficacy and bioavailability.

Additionally, the high blood-brain barrier permeability of atypical South Schisandrium butane suggests its potential application value in neurodegenerative diseases, brain tumors, and other fields. In combination with chemotherapy or targeted therapy, atypical South Schisandra butyl may exert a synergistic effect, reducing resistance and side effects.

However, preclinical and clinical research on it remains limited, and systematic studies on pharmacokinetics, toxicology, and clinical trials need to be strengthened to verify its safety and efficacy. Future research should focus on dosage form optimization, deepening mechanisms of action, and multicenter clinical evaluations to promote clinical application.

Conclusion

As an important lignin natural product of Kadsura species, heterotypic southern schisandra butylene shows broad application prospects especially in the field of liver cancer due to its unique chemical structure and multi-target pharmacological activity. Its anti-lipid peroxidation effect and L-type calcium channel inhibition provide new strategies for controlling the growth of liver cancer cells. Druggability evaluations show that it has good safety and drug properties, but water solubility and bioavailability still need optimization. In the future, through in-depth mechanistic research and preclinical evaluation, atypical South Schisandra butyin is expected to become an important candidate molecule in the development of natural product drugs, bringing new hope for the treatment of liver cancer and related diseases.